Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce L Innis

Showing results (11-20 of 119) with videos related to

Pageof 12
Sort By:
Expert Review of Vaccines|December 8, 2015
Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccinesRafik Bekkat-Berkani, Riju Ray, Varsha K Jain, et al.
BMC Infectious Diseases|March 11, 2014
A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccineVarsha K Jain, Vijayalakshmi Chandrasekaran, Long Wang, et al.
Revista Panamericana De Salud Publica = Pan American Journal of Public Health|September 1, 2007
Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warrantedAlejandro Ellis, Ricardo W Rüttimann, R Jake Jacobs, et al.
The Journal of General Virology|September 25, 2009
Genetic characterization of early isolates of Japanese encephalitis virus: genotype II has been circulating since at least 1951Amy J Schuh, Li Li, Robert B Tesh, et al.
Journal of the Pediatric Infectious Diseases Society|September 26, 2015
Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized TrialLong Wang, Vijayalakshmi Chandrasekaran, Joseph B Domachowske, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|June 12, 2002
Clinical and immunological risk factors for severe disease in Japanese encephalitisDaniel H Libraty, Ananda Nisalak, Timothy P Endy, et al.
Vaccine|June 21, 2005
Cost-effectiveness of universal childhood hepatitis A vaccination in ChileM Teresa Valenzuela, R Jake Jacobs, Oscar Arteaga, et al.
Human Vaccines & Immunotherapeutics|May 24, 2017
A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza controlRiju Ray, Gaël Dos Santos, Philip O Buck, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US childrenRoger Baxter, Robert Jeanfreau, Stanley L Block, et al.
The Journal of Infectious Diseases|March 9, 2013
A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 yearsJoseph B Domachowske, Heidemarie Pankow-Culot, Milagros Bautista, et al.
Pageof 12

Showing results (11-20 of 119) with videos related to

Sort By:
Pageof 12
Expert Review of Vaccines|December 8, 2015
Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccinesRafik Bekkat-Berkani, Riju Ray, Varsha K Jain, et al.
BMC Infectious Diseases|March 11, 2014
A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccineVarsha K Jain, Vijayalakshmi Chandrasekaran, Long Wang, et al.
Revista Panamericana De Salud Publica = Pan American Journal of Public Health|September 1, 2007
Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warrantedAlejandro Ellis, Ricardo W Rüttimann, R Jake Jacobs, et al.
The Journal of General Virology|September 25, 2009
Genetic characterization of early isolates of Japanese encephalitis virus: genotype II has been circulating since at least 1951Amy J Schuh, Li Li, Robert B Tesh, et al.
Journal of the Pediatric Infectious Diseases Society|September 26, 2015
Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized TrialLong Wang, Vijayalakshmi Chandrasekaran, Joseph B Domachowske, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|June 12, 2002
Clinical and immunological risk factors for severe disease in Japanese encephalitisDaniel H Libraty, Ananda Nisalak, Timothy P Endy, et al.
Vaccine|June 21, 2005
Cost-effectiveness of universal childhood hepatitis A vaccination in ChileM Teresa Valenzuela, R Jake Jacobs, Oscar Arteaga, et al.
Human Vaccines & Immunotherapeutics|May 24, 2017
A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza controlRiju Ray, Gaël Dos Santos, Philip O Buck, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US childrenRoger Baxter, Robert Jeanfreau, Stanley L Block, et al.
The Journal of Infectious Diseases|March 9, 2013
A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 yearsJoseph B Domachowske, Heidemarie Pankow-Culot, Milagros Bautista, et al.
Pageof 12